Year archive

Medesis Pharma S.A. — 2023 filings

All 39 regulatory filings released by Medesis Pharma S.A. (ALMDP) in 2023, sourced directly from the official regulator.

39 Filings

2023 Period

2023 filings (39)

Filing	Released	Lang
MEDESIS PHARMA : Apport en trésorerie Capital/Financing Update	2023-12-20	French
MEDESIS PHARMA : ACTIVITÉS & RÉSULTATS DU 1ER SEMESTRE 2023 Interim / Quarterly Report H2 2023	2023-10-27	French
MEDESIS PHARMA: 2023 FIRST-HALF BUSINESS AND EARNINGS Report Publication Announcement H2 2023	2023-10-27	English
MEDESIS PHARMA : RAPPORT FINANCIER SEMESTRIELS 2023 Interim / Quarterly Report H1 2023	2023-10-27	French
MEDESIS PHARMA PARTICIPE AU 16ème CONGRÈS INTERNATIONAL « CLINICAL TRIALS ON ALZHEIMER DISEASE » (CTAD) À BOSTON DU 24 AU 27 OCTOBRE 2023 ET PRÉSENTE UN POSTER SUR SA RECHERCHE EN COURS Regulatory Filings	2023-10-23	French
MEDESIS PHARMA PARTICIPATES IN THE 16th INTERNATIONAL CONGRESS “CLINICAL TRIALS ON ALZHEIMER DISEASE” (CTAD) IN BOSTON FROM OCTOBER 24 TO 27, 2023 AND PRESENTS A POSTER ON ITS CURRENT RESEARCH Regulatory Filings	2023-10-23	English
FIN DU RECRUTEMENT DES 68 PATIENTS DANS L’ÉTUDE CLINIQUE DE PHASE 2 DE MEDESIS PHARMA SUR LE NANOLITHIUM POUR LE TRAITEMENT DE LA MALADIE D’ALZHEIMER Investor Presentation	2023-10-17	French
END OF ENROLLEMENT OF THE 68 PATIENTS IN MEDESIS PHARMA PHASE 2 CLINICAL STUDY OF NANOLITHIUM FOR THE TREATMENT OF ALZHEIMER’S DISEASE Regulatory Filings	2023-10-17	English
MEDESIS PHARMA : AUGMENTATION DES MOYENS ALLOUÉS AU CONTRAT DE LIQUIDITÉ CONCLU AVEC INVEST SECURITIES Regulatory Filings	2023-10-13	French
MEDESIS PHARMA: PUBLICATION OF A SCIENTIFIC ARTICLE IN THE JOURNAL OF ALZHEIMER’S DISEASE ON THE USE OF LITHIUM FOR THE TREATMENT OF ALZHEIMER’S DISEASE Regulatory Filings	2023-10-11	English
MEDESIS PHARMA : PUBLICATION D’UN ARTICLE SCIENTIFIQUE DANS LE JOURNAL OF ALZHEIMER’S DISEASE SUR L’UTILISATION DU LITHIUM POUR LE TRAITEMENT DE LA MALADIE D’ALZHEIMER Regulatory Filings	2023-10-11	French
MEDESIS PHARMA RECEIVES APPROVAL FROM THE MONTPELLIER COMMERCIAL COURT TO OPEN A SAFEGUARD PROCEDURE Legal Proceedings Report	2023-10-03	English
MEDESIS PHARMA OBTIENT UN ACCORD POUR L’OUVERTURE D’UNE PROCÉDURE DE SAUVEGARDE AUPRÈS DU TRIBUNAL DE COMMERCE DE MONTPELLIER Legal Proceedings Report	2023-10-03	French
MEDESIS PHARMA RECOGNIZED AS A 2023 PRIX GALIEN USA NOMINEE FOR BEST STARTUP Regulatory Filings	2023-08-02	English
MEDESIS PHARMA NOMINÉE POUR LE PRIX GALIEN USA 2023 DE LA MEILLEURE STARTUP Regulatory Filings	2023-08-02	French
MEDESIS PHARMA PRÉSENTE UN POSTER SCIENTIFIQUE À LA CONFÉRENCE INTERNATIONALE DE L''ASSOCIATION ALZHEIMER À AMSTERDAM Regulatory Filings	2023-07-13	French
MEDESIS PHARMA PRESENTS A SCIENTIFIC POSTER AT THE INTERNATIONAL CONFERENCE OF THE ALZHEIMER ASSOCIATION IN AMSTERDAM Investor Presentation	2023-07-13	English
MEDESIS PHARMA APPEALS THE DECISION OF THE MONTPELLIER COMMERCIAL COURT IN THE LEGAL DISPUTE WITH BPI FRANCE Legal Proceedings Report	2023-07-06	English
MEDESIS PHARMA : FAIT APPEL DU JUGEMENT DU TRIBUNAL DE COMMERCE DE MONTPELLIER DANS LE CONFLIT JURIDIQUE AVEC BPI FRANCE Legal Proceedings Report	2023-07-06	French
MEDESIS PHARMA: NOTICE OF ALLOWANCE IN THE UNITED STATES OF THE PATENT PROTECTING THE RADIATION PROTECTION TREATMENT AGAINST IRRADIATION DURING A NUCLEAR ACCIDENT Regulatory Filings	2023-07-04	English
MEDESIS PHARMA : ACCORD DE DÉLIVRANCE AUX ETATS-UNIS DU BREVET PROTEGEANT LE TRAITEMENT DE RADIOPROTECTION CONTRE UNE IRRADIATION LORS D’UN ACCIDENT NUCLEAIRE Regulatory Filings	2023-07-04	French
MEDESIS PHARMA: OUTCOME OF THE MONTPELLIER COMMERCIAL COURT RULING IN THE LEGAL DISPUTE BETWEEN MEDESIS PHARMA AND BPI FRANCE Legal Proceedings Report	2023-06-08	English
MEDESIS PHARMA : RÉSULTAT DU JUGEMENT DU TRIBUNAL DE COMMERCE DE MONTPELLIER DANS LE CONFLIT JURIDIQUE ENTRE MEDESIS PHARMA ET BPI FRANCE Legal Proceedings Report	2023-06-08	French
MEDESIS PHARMA : Assemblée Générale Mixte du 15 juin 2023 AGM Information	2023-05-24	French
MEDESIS PHARMA : RAPPORT FAVORABLE DES EXPERTS DE l'IDSMB SUR L’ÉTUDE CLINIQUE DE PHASE 2 EN COURS SUR LE NANOLITHIUM DANS LE TRAITEMENT DE LA MALADIE D’ALZHEIMER Regulatory Filings	2023-05-23	French
MEDESIS PHARMA: FAVORABLE REPORT FROM IDSMB EXPERTS ON THE ONGOING PHASE 2 CLINICAL STUDY ON NANOLITHIUM IN THE TREATMENT OF ALZHEIMER'S DISEASE Legal Proceedings Report	2023-05-23	English
MEDESIS PHARMA : Mise à disposition du Rapport Financier Annuel 2022 Report Publication Announcement	2023-04-27	French
MEDESIS PHARMA : Rapport Financier Annuel 2022 Annual Report FY 2022	2023-04-27	French
MEDESIS PHARMA : 2022 FULL-YEAR BUSINESS AND EARNINGS Earnings Release FY 2022	2023-04-17	English
MEDESIS PHARMA : ACTIVITÉS & RÉSULTATS ANNUELS 2022 Earnings Release FY 2022	2023-04-17	French
MEDESIS PHARMA SIGNS A PARTNERSHIP WITH PARTNER INTERNATIONAL, WORLD LEADER IN TRANSACTIONS BETWEEN BIOTECHS AND PHARMACEUTICAL LABORATORIES Regulatory Filings	2023-04-04	English
MEDESIS PHARMA SIGNE UN PARTENARIAT AVEC PARTNER INTERNATIONAL, LEADER MONDIAL DES TRANSACTIONS ENTRE BIOTECHS ET LABORATOIRES PHARMACEUTIQUES Regulatory Filings	2023-04-04	French
MEDESIS PHARMA MET EN PLACE UN FINANCEMENT OBLIGATAIRE D’UN MONTANT NOMINAL MAXIMUM POTENTIEL DE 2 500 000 EUROS Capital/Financing Update	2023-03-31	French
MEDESIS PHARMA PRESENTE UN POSTER SCIENTIFIQUE AU CONGRES RNA LEADERS EUROPE A BALE Regulatory Filings	2023-03-13	French
MEDESIS PHARMA PRESENTS A SCIENTIFIC POSTER AT THE EUROPEAN RNA LEADERS CONGRESS IN BALE Regulatory Filings	2023-03-13	English
MEDESIS PHARMA: NEW PATENT FILED PROTECTING THE TECHNICAL OPTIMIZATION OF THE AONYS MICROEMULSION AND ITS EFFICACY APPLIED FOR ALL WATER-SOLUBLE PHARMACEUTICAL ACTIVE INGREDIENTS Regulatory Filings	2023-03-07	English
MEDESIS PHARMA : DÉPOT D’UN NOUVEAU BREVET PROTÉGEANT L’OPTIMISATION TECHNIQUE DE LA MICROÉMULSION AONYS ET SON EFFICACITÉ APPLIQUÉE À TOUS LES ACTIFS PHARMACEUTIQUES HYDROSOLUBLES Regulatory Filings	2023-03-07	French
MEDESIS PHARMA : BILAN SEMESTRIEL S2 2022 DU CONTRAT DE LIQUIDITE Net Asset Value	2023-01-05	French
MEDESIS PHARMA CONFIRME SON ELIGIBILITE AU PEA-PME Capital/Financing Update	2023-01-05	French